Press Releases Ziccum AB

Equities

ZICC

SE0011415595

Delayed Nasdaq Stockholm Other stock markets 03:00:52 2024-04-30 am EDT			5-day change	1st Jan Change
6.1 ^SEK	+0.99%		-3.17%	-20.37%

Mar. 14	Ziccum AB Inhalable mRNA/LNP Project Confirms Excellent Properties Obtained by LaminarPace	CI
Mar. 01	Ziccum AB and project partner Zurich institute of Applied Sciences Updates LaminarPace Simulation Project Progress and Findings	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ziccum AB (publ) Interim report Q1 2024	Apr. 29	AQ
Ziccum contracts RFR Solutions for GMP manufacturing in next phase of technology scale-out	Apr. 26	AQ
Ziccum AB (publ) releases Annual Report 2023	Apr. 15	AQ
Ziccum CEO to present at first annual event for Biopharma/Biotech disruptors hosted by major US bank in New York City	Apr. 10	AQ
Ziccum strengthens and streamlines business and finance functions	Apr. 03	AQ
Ziccum inhalable mRNA/LNP project confirms excellent properties obtained by LaminarPace	Mar. 14	AQ
Ziccum reports significant progress in 3D-modelling project with model completion	Mar. 01	AQ
Ziccum announces last day of trading in BTU	Feb. 26	AQ
Ziccum announces outcome in rights issue	Feb. 16	AQ
Ziccums CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family Office	Feb. 12	AQ
Last day for trading in unit rights in Ziccum	Feb. 09	AQ
Ziccum's Board of Directors and Management Group use all their Unit Rights in the ongoing new share issue.	Feb. 08	AQ
Ziccum CEO video interview: mRNA in focus	Feb. 05	AQ
Join Ziccum CEO Ann Gidner for ‘Invest Live’, a live digital presentation and Q&A, Tues Feb 6th	Feb. 03	AQ
Ziccum has proven excellent mRNA activity in animal study with LaminarPace material	Jan. 31	AQ
Ziccum launches IR calendar for coming weeks	Jan. 30	AQ
Ziccum publishes Information Memorandum in connection with the forthcoming rights issue of units	Jan. 30	AQ
ZICCUM AB (publ) Year-End report Q4 2023	Jan. 26	AQ
Ziccum secures financing into 2025 through a combined directed share issue and rights issue to finance the continued execution of its ambitious business plan	Jan. 22	AQ
Ziccum reports successful mRNA/LNP Feasibility Study with major Biotech Corporation	Jan. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ziccum AB

Equities

ZICC

SE0011415595

Press Releases

Filters